Long-Term Cannabis Therapy May Change MS Spasticity Outcomes
Cannabis for MS spasticity was associated with meaningful symptom improvement in a new meta-analysis involving 2,544 multiple sclerosis patients across nine trials. The strongest benefits emerged with longer treatment duration, while short-term effects…
Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.
A new consensus from Italian neurologists proposes enhancing the endocannabinoid system multiple sclerosis treatment approach for patients with relapse-free disease. The algorithm combines cannabinoid agents with lifestyle interventions to address…
Persistent and Debilitating Muscle Spasms | Utah Medical Cannabis Guidelines
Utah's spasticity clinical guidelines provide evidence-based protocols for medical cannabis use in persistent and debilitating muscle spasms. These guidelines help clinicians with dosing and delivery methods for spasticity management. Patients with…
Over 70% of MS Patients in Rehab Take 5+ Medications, Study Finds
Polypharmacy in MS rehabilitation is a significant clinical challenge, with over 70% of patients taking five or more medications. This study highlights the potential for cannabis to consolidate therapies and reduce drug interactions. Understanding…
Honoring the Trailblazers with MS Who Changed Cannabis Policy
Multiple sclerosis cannabis advocacy has played a pivotal role in shaping medical cannabis policy. MS patients were among the first to demonstrate therapeutic benefits of cannabinoids in clinical settings. Their efforts helped establish evidence-based…
MS Cases Double in England Over 20 Years; Life Expectancy Rises
Multiple sclerosis spasticity cannabis treatments are gaining attention as MS cases double in England over 20 years. Improved survival rates mean more patients live longer with chronic symptoms. Cannabis therapies offer promising options for managing…
Investigating Medicinal Cannabis for Muscle Spasticity and Spasms
This muscle spasticity cannabis study evaluates the effectiveness and adverse events of medicinal cannabis in patients with muscle spasticity or spasms. CBD-only products showed meaningful improvements in sleep disturbance, fatigue, and pain interference…
Cannabis for MS Spasticity: A Systematic Review With Critically Unreliable Pooled Estimates
This cannabis MS spasticity review examines nine trials with 2,544 patients but finds critically unreliable pooled estimates due to extreme heterogeneity. The meta-analysis reports numerically implausible effect sizes and suspected publication bias.…
Enhancing Endocannabinoid System for Residual Disease in MS
This clinical study endocannabinoid system approach addresses residual disease in relapse-free multiple sclerosis patients. High-efficacy therapies reduce relapses but symptoms persist. Enhancing the endocannabinoid system offers new treatment insights.
